More Clinuvel Pharmaceuticals Limited news
Clinuvel Pharmaceuticals LimitedASX: CUV

Observations from Clinuvel`s programs being presented at AAD

Mar 30, 2016 at 2:14 AM EDT · Issued by Clinuvel Pharmaceuticals Limited

Filed with ASX · Mar 30, 2016 at 2:14 AM EDT

On 6ix: 6ix.com/news/observations-from-clinuvels-programs-being-presented-at-aad

Watch Clinuvel Pharmaceuticals' latest call↗Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call↗

View Attachment

6ix hasn’t read this filing yet.

Clinuvel Pharmaceuticals Limited on 6ix

Story so far

  • FDA allows Clinuvel`s innovative vitiligo trialFeb 11, 2016
  • Swiss insurers agree to reimburse Clinuvel`s SCENESSEFeb 11, 2016
  • First positive observations from Clinuvel`s vitiligo trialFeb 11, 2016

Earlier from Clinuvel Pharmaceuticals

  • SCENESSE successful in Phase IIa vitiligo studyMar 30, 2016
  • PlacementMar 30, 2016

Later from Clinuvel Pharmaceuticals

  • Clinuvel books European Pre-Submission Meeting for SCENESSEMar 30, 2016
  • Clinuvel completes first Phase II US studyMar 30, 2016
  • Clinuvel granted Australian formulation patentMar 30, 2016
  • Clinuvel presents SCENESSE to global porphyria conferenceMar 30, 2016
  • Clinuvel records first A$1 million in salesMar 30, 2016
All Clinuvel Pharmaceuticals news releases↗

Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.

Follow Clinuvel Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer